Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

09th June 2022
Introduction: To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make...
Learn More

Exosome & Extracellular Vesical-Based Therapeutics & Their Potential Use in Oncology

12th November 2021
Abstract It was previously believed that exosomes, membrane-bound extracellular vesicles released by cells, were a waste disposal mechanism resulting from cell damage or from by-products of cell...
Learn More

The emerging landscape of RNA-targeted small molecules

17th September 2021
Intro: For decades, conventional drug strategy has relied on the ability of small molecules to either inhibit or alter protein function by targeting their active sites. While this was instrumental in...
Learn More

Replacing the Surrogates: Beyond In Vivo Preclinical Models

24th August 2021
Intro: Animal modelling is a staple of preclinical drug development and in most countries a legal requirement before entering human trials. However, these experiments are time-consuming, expensive,...
Learn More

What's on Pharma's Licensing Wish List?

04th August 2021
Asset licensing, mergers, and acquisitions have become an integral pipeline expansion strategy for Pharma. The realization over the past two decades that productivity of internal R&D alone is...
Learn More

Cell Therapy for Autoimmune Disease: Landscape Analysis & Overview

01st February 2021
The cell therapy field has been predominantly active in the oncology space and is enjoying bench-to-bedside clinical success. However, the cancer cell therapy space has become very crowded and drug...
Learn More

Cellular Immunotherapy: Challenges and Potential Solutions

18th August 2020
It would not be an overstatement to say that in recent years cellular immunotherapies have demonstrated great therapeutic success in some cancers. However, several technical difficulties remain that...
Learn More

An Analysis of the Cellular Immunotherapy Landscape for Cancer

20th June 2020
Types of cellular immunotherapy:  Cellular immunotherapies involve modifying autologous or allogeneic immune cells through genetic engineering or modulation of the protein expression profile, then...
Learn More

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome

11th November 2019
The purpose of this analysis of patient-reported outcomes from the ELECT (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to...
Learn More

Valuing Pharmaceutical Assets: When to Use NPV vs rNPV

15th October 2019
Preview: A variety of approaches have been developed to evaluate pharmaceutical assets, but two similar yet distinct methods are most commonly used. Venture capitalists and large investment firms...
Learn More

Adeno-Associated Virus Gene Therapy Landscape

24th September 2019
Adeno-associated viruses (AAV) are virus particles composed of single-stranded DNA surrounded by a protein shell. Despite their simple structure, recombinant AAVs (rAAV) can perform the important...
Learn More

Pharmaceutical Due Diligence Checklist | Biotech Due Diligence

23rd August 2019
For more than a decade, Alacrita has been an expert resource for due diligence and valuation services covering pharmaceuticals and biotechnology. This paper shares some of the insights we've learned...
Learn More
1 2 3
Next
Content not found

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.